{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T02:14:18Z","timestamp":1792548858146,"version":"4.5.0"},"reference-count":113,"publisher":"Hindawi Limited","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":103,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Neurol Scand"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1111\/ane.12444","type":"journal-article","created":{"date-parts":[[2015,5,21]],"date-time":"2015-05-21T11:23:36Z","timestamp":1432207416000},"page":"84-96","source":"Crossref","is-referenced-by-count":20,"title":["Intravenous immunoglobulin in the treatment of neurologic disorders"],"prefix":"10.1155","volume":"133","author":[{"given":"S.","family":"\u017divkovi\u0107","sequence":"first","affiliation":[{"name":"Department of Neurology; University of Pittsburgh Medical Center; Pittsburgh PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"98","published-online":{"date-parts":[[2015,5,21]]},"reference":[{"key":"10.1111\/ane.12444-BIB0001|ane12444-cit-0001","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.iac.2008.06.002","article-title":"Intravenous immunoglobulins: evolution of commercial IVIG preparations","volume":"28","author":"Hooper","year":"2008","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1111\/ane.12444-BIB0002|ane12444-cit-0002","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1056\/NEJMra993360","article-title":"Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin","volume":"345","author":"Kazatchkine","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1111\/ane.12444-BIB0003|ane12444-cit-0003","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/nri3401","article-title":"Intravenous immunoglobulin therapy: how does IgG modulate the immune system?","volume":"13","author":"Schwab","year":"2013","journal-title":"Nat Rev Immunol"},{"issue":"Suppl 1","key":"10.1111\/ane.12444-BIB0004|ane12444-cit-0004","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2249.2009.04022.x","article-title":"Intravenous immunoglobulins-understanding properties and mechanisms","volume":"158","author":"Durandy","year":"2009","journal-title":"Clin Exp Immunol"},{"key":"10.1111\/ane.12444-BIB0005|ane12444-cit-0005","volume-title":"Third national immunoglobulin database report (2012)","author":"O'Shaugnessy","year":"2013"},{"key":"10.1111\/ane.12444-BIB0006|ane12444-cit-0006","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1001\/jama.291.19.2367","article-title":"Intravenous immunoglobulin in autoimmune neuromuscular diseases","volume":"291","author":"Dalakas","year":"2004","journal-title":"JAMA"},{"key":"10.1111\/ane.12444-BIB0007|ane12444-cit-0007","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1468-1331.2008.02246.x","article-title":"EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases","volume":"15","author":"Elovaara","year":"2008","journal-title":"Eur J Neurol"},{"key":"10.1111\/ane.12444-BIB0008|ane12444-cit-0008","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1212\/WNL.0b013e31824de293","article-title":"Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology","volume":"78","author":"Patwa","year":"2012","journal-title":"Neurology"},{"issue":"Suppl 1","key":"10.1111\/ane.12444-BIB0009|ane12444-cit-0009","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1007\/s10875-012-9789-6","article-title":"Treatment of neurological autoimmune diseases with immunoglobulins: first insights from the prospective SIGNS registry","volume":"33","author":"Stangel","year":"2013","journal-title":"J Clin Immunol"},{"issue":"Suppl 1","key":"10.1111\/ane.12444-BIB0010|ane12444-cit-0010","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.1007\/s10875-014-0024-5","article-title":"Mechanistic effects of IVIg in neuroinflammatory diseases: conclusions based on clinicopathologic correlations","volume":"34","author":"Dalakas","year":"2014","journal-title":"J Clin Immunol"},{"key":"10.1111\/ane.12444-BIB0011|ane12444-cit-0011","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1007\/s00415-014-7444-2","article-title":"Subcutaneous immunoglobulin in CIDP and MMN: a short-term nationwide study","volume":"261","author":"Cocito","year":"2014","journal-title":"J Neurol"},{"key":"10.1111\/ane.12444-BIB0012|ane12444-cit-0012","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1111\/ene.12513","article-title":"Subcutaneous immunoglobulin preserves muscle strength in chronic inflammatory demyelinating polyneuropathy","volume":"21","author":"Markvardsen","year":"2014","journal-title":"Eur J Neurol"},{"issue":"12 Suppl 6","key":"10.1111\/ane.12444-BIB0013|ane12444-cit-0013","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1212\/WNL.59.12_suppl_6.S28","article-title":"Composition and properties of IVIg preparations that affect tolerability and therapeutic efficacy","volume":"59","author":"Lemm","year":"2002","journal-title":"Neurology"},{"key":"10.1111\/ane.12444-BIB0014|ane12444-cit-0014","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1136\/jnnp.2010.206599","article-title":"Randomised controlled trial comparing two different intravenous immunoglobulins in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"81","author":"Kuitwaard","year":"2010","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1111\/ane.12444-BIB0015|ane12444-cit-0015","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.clim.2011.01.006","article-title":"Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies","volume":"139","author":"Berger","year":"2011","journal-title":"Clin Immunol"},{"key":"10.1111\/ane.12444-BIB0016|ane12444-cit-0016","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.jaci.2012.06.021","article-title":"Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency","volume":"130","author":"Wasserman","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1111\/ane.12444-BIB0017|ane12444-cit-0017","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1093\/brain\/awh518","article-title":"Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes","volume":"128","author":"Raju","year":"2005","journal-title":"Brain"},{"key":"10.1111\/ane.12444-BIB0018|ane12444-cit-0018","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2014-307708","article-title":"Effective treatment with intravenous immunoglobulins reduces autoreactive T-cell response in patients with CIDP","author":"Klehmet","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1111\/ane.12444-BIB0019|ane12444-cit-0019","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jneuroim.2014.06.007","article-title":"IVIG regulates BAFF expression in patients with chronic inflammatory demyelinating polyneuropathy (CIDP)","volume":"274","author":"Ritter","year":"2014","journal-title":"J Neuroimmunol"},{"key":"10.1111\/ane.12444-BIB0020|ane12444-cit-0020","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jneuroim.2007.11.020","article-title":"A disease-specific fraction isolated from IVIG is essential for the immunosuppressive effect of IVIG in experimental autoimmune myasthenia gravis","volume":"194","author":"Fuchs","year":"2008","journal-title":"J Neuroimmunol"},{"key":"10.1111\/ane.12444-BIB0021|ane12444-cit-0021","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1172\/JCI117520","article-title":"High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments","volume":"94","author":"Basta","year":"1994","journal-title":"J Clin Investig"},{"key":"10.1111\/ane.12444-BIB0022|ane12444-cit-0022","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.iac.2008.06.006","article-title":"Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes","volume":"28","author":"Bonilla","year":"2008","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1111\/ane.12444-BIB0023|ane12444-cit-0023","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/ana.21737","article-title":"Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barre syndrome","volume":"66","author":"Kuitwaard","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1111\/ane.12444-BIB0024|ane12444-cit-0024","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1136\/jnnp-2013-306227","article-title":"Pharmacokinetics of intravenous immunoglobulin in multifocal motor neuropathy","volume":"85","author":"Vlam","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1111\/ane.12444-BIB0025|ane12444-cit-0025","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1212\/WNL.44.2.223","article-title":"High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events","volume":"44","author":"Dalakas","year":"1994","journal-title":"Neurology"},{"key":"10.1111\/ane.12444-BIB0026|ane12444-cit-0026","doi-asserted-by":"crossref","first-page":"259","DOI":"10.7326\/0003-4819-121-4-199408150-00004","article-title":"Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors","volume":"121","author":"Sekul","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1111\/ane.12444-BIB0027|ane12444-cit-0027","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1097\/MOP.0b013e328365ad3f","article-title":"Pediatric Guillain-Barre syndrome","volume":"25","author":"Ryan","year":"2013","journal-title":"Curr Opin Pediatr"},{"key":"10.1111\/ane.12444-BIB0028|ane12444-cit-0028","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1002\/mus.21058","article-title":"What is the best initial treatment for childhood chronic inflammatory demyelinating polyneuropathy: corticosteroids or intravenous immunoglobulin?","volume":"38","author":"Sladky","year":"2008","journal-title":"Muscle Nerve"},{"key":"10.1111\/ane.12444-BIB0029|ane12444-cit-0029","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1529-8027.2009.00218.x","article-title":"Subcutaneous immunoglobulin therapy for multifocal motor neuropathy","volume":"14","author":"Eftimov","year":"2009","journal-title":"J Peripher Nerv Syst"},{"key":"10.1111\/ane.12444-BIB0030|ane12444-cit-0030","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/jns5.12053","article-title":"Chronic inflammatory demyelinating polyradiculoneuropathy and variants: where we are and where we should go","volume":"19","author":"Nobile-Orazio","year":"2014","journal-title":"J Peripher Nerv Syst"},{"key":"10.1111\/ane.12444-BIB0031|ane12444-cit-0031","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S1474-4422(12)70093-5","article-title":"Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial","volume":"11","author":"Nobile-Orazio","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1111\/ane.12444-BIB0032|ane12444-cit-0032","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S1474-4422(07)70329-0","article-title":"Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial","volume":"7","author":"Hughes","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1111\/ane.12444-BIB0033|ane12444-cit-0033","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1136\/jnnp.2005.065441","article-title":"Long term prognosis of chronic inflammatory demyelinating polyneuropathy: a five year follow up of 38 cases","volume":"77","author":"Kuwabara","year":"2006","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1111\/ane.12444-BIB0034|ane12444-cit-0034","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1529-8027.2010.00284.x","article-title":"Chronic inflammatory demyelinating polyneuropathy disease activity status: recommendations for clinical research standards and use in clinical practice","volume":"15","author":"Gorson","year":"2010","journal-title":"J Peripher Nerv Syst"},{"key":"10.1111\/ane.12444-BIB0035|ane12444-cit-0035","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1001\/archneurol.2010.105","article-title":"Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"67","author":"Latov","year":"2010","journal-title":"Arch Neurol"},{"key":"10.1111\/ane.12444-BIB0036|ane12444-cit-0036","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1212\/WNL.61.6.736","article-title":"Practice parameter: immunotherapy for Guillain-Barre syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"61","author":"Hughes","year":"2003","journal-title":"Neurology"},{"key":"10.1111\/ane.12444-BIB0037|ane12444-cit-0037","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1093\/brain\/awm004","article-title":"Immunotherapy for Guillain-Barre syndrome: a systematic review","volume":"130","author":"Hughes","year":"2007","journal-title":"Brain"},{"key":"10.1111\/ane.12444-BIB0038|ane12444-cit-0038","first-page":"CD002063","article-title":"Intravenous immunoglobulin for Guillain-Barre syndrome","volume":"7","author":"Hughes","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1111\/ane.12444-BIB0039|ane12444-cit-0039","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1136\/jnnp.71.2.235","article-title":"Intravenous immune globulins in patients with Guillain-Barre syndrome and contraindications to plasma exchange: 3\u00a0days versus 6\u00a0days","volume":"71","author":"Raphael","year":"2001","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1111\/ane.12444-BIB0040|ane12444-cit-0040","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/S0140-6736(97)24050-X","article-title":"Efficacy of repeated intravenous immunoglobulin in severe unresponsive Guillain-Barre syndrome","volume":"350","author":"Farcas","year":"1997","journal-title":"Lancet"},{"key":"10.1111\/ane.12444-BIB0041|ane12444-cit-0041","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1056\/NEJM199204233261705","article-title":"A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. Dutch Guillain-Barre Study Group","volume":"326","author":"Meche","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1111\/ane.12444-BIB0042|ane12444-cit-0042","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/CND.0b013e318182b5ce","article-title":"Immunotherapy for Guillain-Barre syndrome in the US hospitals","volume":"10","author":"Alshekhlee","year":"2008","journal-title":"J Clin Neuromuscul Dis"},{"key":"10.1111\/ane.12444-BIB0043|ane12444-cit-0043","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1212\/WNL.0b013e3181f0738e","article-title":"Correlates of outcome and response to IVIg in 88 patients with multifocal motor neuropathy","volume":"75","author":"Cats","year":"2010","journal-title":"Neurology"},{"key":"10.1111\/ane.12444-BIB0044|ane12444-cit-0044","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/jns5.12046","article-title":"A controlled trial of intravenous immunoglobulin in multifocal motor neuropathy","volume":"18","author":"Hahn","year":"2013","journal-title":"J Peripher Nerv Syst"},{"key":"10.1111\/ane.12444-BIB0045|ane12444-cit-0045","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1212\/WNL.31.11.1480","article-title":"Prevalence of monoclonal protein in peripheral neuropathy","volume":"31","author":"Kelly","year":"1981","journal-title":"Neurology"},{"key":"10.1111\/ane.12444-BIB0046|ane12444-cit-0046","first-page":"CD002827","article-title":"Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies","volume":"5","author":"Lunn","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1111\/ane.12444-BIB0047|ane12444-cit-0047","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1001\/archneur.59.5.766","article-title":"Efficacy of intravenous immunoglobulin in patients with IgG monoclonal gammopathy and polyneuropathy","volume":"59","author":"Gorson","year":"2002","journal-title":"Arch Neurol"},{"key":"10.1111\/ane.12444-BIB0048|ane12444-cit-0048","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1080\/10428190903111922","article-title":"Paraproteinemic neuropathy","volume":"50","author":"Zivkovic","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1111\/ane.12444-BIB0049|ane12444-cit-0049","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1212\/WNL.54.3.615","article-title":"Distal acquired demyelinating symmetric neuropathy","volume":"54","author":"Katz","year":"2000","journal-title":"Neurology"},{"key":"10.1111\/ane.12444-BIB0050|ane12444-cit-0050","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1093\/brain\/123.4.710","article-title":"Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies","volume":"123","author":"Nobile-Orazio","year":"2000","journal-title":"Brain"},{"key":"10.1111\/ane.12444-BIB0051|ane12444-cit-0051","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.ncl.2014.04.007","article-title":"Idiopathic inflammatory myopathies","volume":"32","author":"Dimachkie","year":"2014","journal-title":"Neurol Clin"},{"key":"10.1111\/ane.12444-BIB0052|ane12444-cit-0052","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s10067-013-2478-x","article-title":"Open-label study on treatment with 20% subcutaneous IgG administration in polymyositis and dermatomyositis","volume":"33","author":"Danieli","year":"2014","journal-title":"Clin Rheumatol"},{"key":"10.1111\/ane.12444-BIB0053|ane12444-cit-0053","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","article-title":"A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis","volume":"329","author":"Dalakas","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1111\/ane.12444-BIB0054|ane12444-cit-0054","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/art.10053","article-title":"Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients","volume":"46","author":"Cherin","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1111\/ane.12444-BIB0055|ane12444-cit-0055","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/MD.0000000000000028","article-title":"Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin","volume":"93","author":"Allenbach","year":"2014","journal-title":"Medicine"},{"key":"10.1111\/ane.12444-BIB0056|ane12444-cit-0056","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1093\/brain\/awr213","article-title":"Long-term observational study of sporadic inclusion body myositis","volume":"134","author":"Benveniste","year":"2011","journal-title":"Brain"},{"key":"10.1111\/ane.12444-BIB0057|ane12444-cit-0057","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1212\/WNL.48.3.712","article-title":"Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study","volume":"48","author":"Dalakas","year":"1997","journal-title":"Neurology"},{"key":"10.1111\/ane.12444-BIB0058|ane12444-cit-0058","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1468-1331.2010.03019.x","article-title":"Guidelines for treatment of autoimmune neuromuscular transmission disorders","volume":"17","author":"Skeie","year":"2010","journal-title":"Eur J Neurol"},{"key":"10.1111\/ane.12444-BIB0059|ane12444-cit-0059","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1212\/WNL.52.3.629","article-title":"Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis","volume":"52","author":"Qureshi","year":"1999","journal-title":"Neurology"},{"key":"10.1111\/ane.12444-BIB0060|ane12444-cit-0060","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","article-title":"Comparison of IVIg and PLEX in patients with myasthenia gravis","volume":"76","author":"Barth","year":"2011","journal-title":"Neurology"},{"key":"10.1111\/ane.12444-BIB0061|ane12444-cit-0061","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1001\/jamaneurol.2014.17","article-title":"Comparison of plasmapheresis and intravenous immunoglobulin as maintenance therapies for juvenile myasthenia gravis","volume":"71","author":"Liew","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.1111\/ane.12444-BIB0062|ane12444-cit-0062","first-page":"CD002277","article-title":"Intravenous immunoglobulin for myasthenia gravis","volume":"12","author":"Gajdos","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1111\/ane.12444-BIB0063|ane12444-cit-0063","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/mus.22006","article-title":"Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts","volume":"44","author":"Guptill","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1111\/ane.12444-BIB0064|ane12444-cit-0064","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1212\/WNL.42.7.1422","article-title":"Clinical and electrophysiologic improvement in Lambert-Eaton syndrome with intravenous immunoglobulin therapy","volume":"42","author":"Bird","year":"1992","journal-title":"Neurology"},{"issue":"2","key":"10.1111\/ane.12444-BIB0065|ane12444-cit-0065","first-page":"CD003279","article-title":"Treatment for Lambert-Eaton myasthenic syndrome","author":"Keogh","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1111\/ane.12444-BIB0066|ane12444-cit-0066","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0303-8467(00)00093-7","article-title":"Successful immunoglobulin treatment in a patient with neuromyotonia","volume":"102","author":"Alessi","year":"2000","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1111\/ane.12444-BIB0067|ane12444-cit-0067","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1196\/annals.1361.121","article-title":"Response of vasculitic peripheral neuropathy to intravenous immunoglobulin","volume":"1051","author":"Levy","year":"2005","journal-title":"Ann N Y Acad Sci"},{"key":"10.1111\/ane.12444-BIB0068|ane12444-cit-0068","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1002\/acr.20495","article-title":"Experience of intravenous immunoglobulin therapy in neuropathy associated with primary Sjogren's syndrome: a national multicentric retrospective study","volume":"63","author":"Rist","year":"2011","journal-title":"Arthritis Care Res"},{"key":"10.1111\/ane.12444-BIB0069|ane12444-cit-0069","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa01167","article-title":"High-dose intravenous immune globulin for stiff-person syndrome","volume":"345","author":"Dalakas","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1111\/ane.12444-BIB0070|ane12444-cit-0070","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s004150050350","article-title":"Intravenous immunoglobulins in the therapy of paraneoplastic neurological disorders","volume":"246","author":"Blaes","year":"1999","journal-title":"J Neurol"},{"key":"10.1111\/ane.12444-BIB0071|ane12444-cit-0071","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1111\/j.1528-1167.2007.01134.x","article-title":"Intravenous immunoglobulins in refractory childhood-onset epilepsy: effects on seizure frequency, EEG activity, and cerebrospinal fluid cytokine profile","volume":"48","author":"Billiau","year":"2007","journal-title":"Epilepsia"},{"key":"10.1111\/ane.12444-BIB0072|ane12444-cit-0072","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1212\/01.wnl.0000318281.98220.6f","article-title":"Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial","volume":"71","author":"Fazekas","year":"2008","journal-title":"Neurology"},{"issue":"Suppl 1","key":"10.1111\/ane.12444-BIB0073|ane12444-cit-0073","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1007\/s10875-012-9796-7","article-title":"Neuromyelitis optica: potential roles for intravenous immunoglobulin","volume":"33","author":"Wingerchuk","year":"2013","journal-title":"J Clin Immunol"},{"key":"10.1111\/ane.12444-BIB0074|ane12444-cit-0074","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1038\/jcbfm.2013.160","article-title":"Brain bioavailability of human intravenous immunoglobulin and its transport through the murine blood-brain barrier","volume":"33","author":"St-Amour","year":"2013","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1111\/ane.12444-BIB0075|ane12444-cit-0075","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1093\/brain\/awh297","article-title":"IVIg therapy in brain inflammation: etiology-dependent differential effects on leucocyte recruitment","volume":"127","author":"Lapointe","year":"2004","journal-title":"Brain"},{"key":"10.1111\/ane.12444-BIB0076|ane12444-cit-0076","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jneuroim.2009.01.014","article-title":"Therapeutic activities of intravenous immunoglobulins in multiple sclerosis involve modulation of chemokine expression","volume":"209","author":"Pigard","year":"2009","journal-title":"J Neuroimmunol"},{"key":"10.1111\/ane.12444-BIB0077|ane12444-cit-0077","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(04)17101-8","article-title":"Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial","volume":"364","author":"Hommes","year":"2004","journal-title":"Lancet"},{"key":"10.1111\/ane.12444-BIB0078|ane12444-cit-0078","first-page":"CD008933","article-title":"Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis","volume":"6","author":"Filippini","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1111\/ane.12444-BIB0079|ane12444-cit-0079","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1212\/WNL.56.11.1514","article-title":"A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis","volume":"56","author":"Noseworthy","year":"2001","journal-title":"Neurology"},{"key":"10.1111\/ane.12444-BIB0080|ane12444-cit-0080","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s00415-004-0495-z","article-title":"Effect of intravenous immunoglobulin treatment on pregnancy and postpartum-related relapses in multiple sclerosis","volume":"251","author":"Achiron","year":"2004","journal-title":"J Neurol"},{"key":"10.1111\/ane.12444-BIB0081|ane12444-cit-0081","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1212\/WNL.0b013e31823dc535","article-title":"Evidence-based guideline: clinical evaluation and treatment of transverse myelitis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology","volume":"77","author":"Scott","year":"2011","journal-title":"Neurology"},{"key":"10.1111\/ane.12444-BIB0082|ane12444-cit-0082","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1046\/j.1468-1331.2003.00543.x","article-title":"Subacute rhombencephalitis optica responsive to intravenous immunoglobulins","volume":"10","author":"Zivkovic","year":"2003","journal-title":"Eur J Neurol"},{"key":"10.1111\/ane.12444-BIB0083|ane12444-cit-0083","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.autrev.2011.05.008","article-title":"Immune-mediated CNS diseases: a review on nosological classification and clinical features","volume":"11","author":"Zettl","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1111\/ane.12444-BIB0084|ane12444-cit-0084","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1212\/WNL.54.6.1370","article-title":"Treatment of acute disseminated encephalomyelitis with intravenous immunoglobulin","volume":"54","author":"Sahlas","year":"2000","journal-title":"Neurology"},{"key":"10.1111\/ane.12444-BIB0085|ane12444-cit-0085","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1017\/S0317167100015304","article-title":"Immunomodulation in adult epilepsy: the role of IVIG","volume":"39","author":"Sharp","year":"2012","journal-title":"Can J Neurol Sci"},{"key":"10.1111\/ane.12444-BIB0086|ane12444-cit-0086","first-page":"CD009945","article-title":"Immunomodulatory interventions for focal epilepsy syndromes","volume":"6","author":"Walker","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1111\/ane.12444-BIB0087|ane12444-cit-0087","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/imm.12233","article-title":"Inflammation in neurodegenerative diseases-an update","volume":"142","author":"Amor","year":"2014","journal-title":"Immunology"},{"key":"10.1111\/ane.12444-BIB0088|ane12444-cit-0088","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S1474-4422(13)70014-0","article-title":"Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial","volume":"12","author":"Dodel","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1111\/ane.12444-BIB0089|ane12444-cit-0089","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1055\/s-0031-1277985","article-title":"Autoimmune encephalopathy","volume":"31","author":"Flanagan","year":"2011","journal-title":"Semin Neurol"},{"key":"10.1111\/ane.12444-BIB0090|ane12444-cit-0090","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1097\/00043426-199911000-00012","article-title":"Corticosteroid prophylaxis for neurologic complications of intravenous immunoglobulin G therapy in childhood immune thrombocytopenic purpura","volume":"21","author":"Jayabose","year":"1999","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1111\/ane.12444-BIB0091|ane12444-cit-0091","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00415-009-0969-0","article-title":"Case-control study of thromboembolic events associated with IV immunoglobulin","volume":"256","author":"Caress","year":"2009","journal-title":"J Neurol"},{"key":"10.1111\/ane.12444-BIB0092|ane12444-cit-0092","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1001\/archneurol.2010.223","article-title":"Safety and tolerability of immune globulin intravenous in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"67","author":"Donofrio","year":"2010","journal-title":"Arch Neurol"},{"key":"10.1111\/ane.12444-BIB0093|ane12444-cit-0093","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1212\/01.WNL.0000068335.01620.9D","article-title":"The clinical features of 16 cases of stroke associated with administration of IVIg","volume":"60","author":"Caress","year":"2003","journal-title":"Neurology"},{"key":"10.1111\/ane.12444-BIB0094|ane12444-cit-0094","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.semarthrit.2004.06.003","article-title":"Intravenous immunoglobulin and the kidney-a two-edged sword","volume":"34","author":"Orbach","year":"2004","journal-title":"Semin Arthritis Rheum"},{"key":"10.1111\/ane.12444-BIB0095|ane12444-cit-0095","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.2215\/CJN.04540709","article-title":"Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients","volume":"4","author":"Kahwaji","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1111\/ane.12444-BIB0096|ane12444-cit-0096","first-page":"505","article-title":"Outbreak of hepatitis C associated with intravenous immunoglobulin administration-United States, October 1993-June 1994","volume":"43","author":"Centers for Disease Control and Prevention","year":"1994","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1111\/ane.12444-BIB0097|ane12444-cit-0097","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1423-0410.2007.01016.x","article-title":"A new liquid intravenous immunoglobulin with three dedicated virus reduction steps: virus and prion reduction capacity","volume":"94","author":"Poelsler","year":"2008","journal-title":"Vox Sang"},{"key":"10.1111\/ane.12444-BIB0098|ane12444-cit-0098","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000350287","article-title":"Optimization of intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy evaluated by grip strength measurement","volume":"70","author":"Kokubun","year":"2013","journal-title":"Eur Neurol"},{"key":"10.1111\/ane.12444-BIB0099|ane12444-cit-0099","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1007\/s00415-013-6938-7","article-title":"Immunoglobulin G level variations in treated chronic inflammatory demyelinating polyneuropathy: clues for future treatment regimens?","volume":"260","author":"Rajabally","year":"2013","journal-title":"J Neurol"},{"key":"10.1111\/ane.12444-BIB0100|ane12444-cit-0100","first-page":"309","article-title":"Can we face the challenge of expanding use of intravenous immunoglobulin in neurology?","volume":"122","author":"Elovaara","year":"2010","journal-title":"Acta Neurol Scand"},{"key":"10.1111\/ane.12444-BIB0101|ane12444-cit-0101","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.iac.2008.06.008","article-title":"Economic assessment of different modalities of immunoglobulin replacement therapy","volume":"28","author":"Membe","year":"2008","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1111\/ane.12444-BIB0102|ane12444-cit-0102","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S1474-4422(06)70447-1","article-title":"Intravenous immunoglobulin for post-polio syndrome: a randomised control study","volume":"5","author":"Gonzalez","year":"2006","journal-title":"Lancet Neurol"},{"key":"10.1111\/ane.12444-BIB0103|ane12444-cit-0103","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1212\/WNL.0b013e31825dce83","article-title":"Level of evidence reviews: three years of progress","volume":"79","author":"Ashman","year":"2012","journal-title":"Neurology"},{"key":"10.1111\/ane.12444-BIB0104|ane12444-cit-0104","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/0140-6736(93)92000-J","article-title":"Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura","volume":"342","author":"Debre","year":"1993","journal-title":"Lancet"},{"key":"10.1111\/ane.12444-BIB0105|ane12444-cit-0105","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1182\/blood-2002-05-1447","article-title":"Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin","volume":"101","author":"Bayry","year":"2003","journal-title":"Blood"},{"key":"10.1111\/ane.12444-BIB0106|ane12444-cit-0106","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1126\/science.1154315","article-title":"Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc","volume":"320","author":"Anthony","year":"2008","journal-title":"Science"},{"key":"10.1111\/ane.12444-BIB0107|ane12444-cit-0107","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1016\/j.molimm.2008.07.012","article-title":"Ambivalent effect of immunoglobulins on the complement system: activation versus inhibition","volume":"45","author":"Basta","year":"2008","journal-title":"Mol Immunol"},{"key":"10.1111\/ane.12444-BIB0108|ane12444-cit-0108","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.it.2008.08.004","article-title":"Modulation of the cellular immune system by intravenous immunoglobulin","volume":"29","author":"Tha-In","year":"2008","journal-title":"Trends Immunol"},{"key":"10.1111\/ane.12444-BIB0109|ane12444-cit-0109","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/jns5.12048","article-title":"Rapid and reversible responses to IVIG in autoimmune neuromuscular diseases suggest mechanisms of action involving competition with functionally important autoantibodies","volume":"18","author":"Berger","year":"2013","journal-title":"J Peripher Nerv Syst"},{"issue":"Suppl 1","key":"10.1111\/ane.12444-BIB0110|ane12444-cit-0110","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1007\/s10875-010-9398-1","article-title":"Mechanisms of IVIG efficacy in chronic inflammatory demyelinating polyneuropathy","volume":"30","author":"Tackenberg","year":"2010","journal-title":"J Clin Immunol"},{"issue":"Suppl 1","key":"10.1111\/ane.12444-BIB0111|ane12444-cit-0111","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1007\/s10875-014-0019-2","article-title":"Natural autoantibodies to Fcgamma receptors in intravenous immunoglobulins","volume":"34","author":"Bouhlal","year":"2014","journal-title":"J Clin Immunol"},{"key":"10.1111\/ane.12444-BIB0112|ane12444-cit-0112","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1016\/j.molimm.2007.12.020","article-title":"Monomerization of dimeric IgG of intravenous immunoglobulin (IVIg) increases the antibody reactivity against intracellular antigens","volume":"45","author":"Wymann","year":"2008","journal-title":"Mol Immunol"},{"issue":"Suppl 1","key":"10.1111\/ane.12444-BIB0113|ane12444-cit-0113","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1007\/s10875-014-0018-3","article-title":"Fc glycan-modulated immunoglobulin G effector functions","volume":"34","author":"Quast","year":"2014","journal-title":"J Clin Immunol"}],"container-title":["Acta Neurologica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fane.12444","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/ane.12444\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T12:48:40Z","timestamp":1671540520000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ane.12444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,21]]},"references-count":113,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"URL":"https:\/\/doi.org\/10.1111\/ane.12444","archive":["Portico"],"relation":{},"ISSN":["0001-6314"],"issn-type":[{"value":"0001-6314","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5,21]]}}}